Role of prostate stem cell antigen in prostate cancer research

Current Opinion in Urology

Volumn 12, Issue 5, 2002, Pages 401-406

  Jalkut, Mark W ^a   Reiter, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Prostate cancer; Prostate stem cell antigen

Indexed keywords

ANTIBODY CONJUGATE; CELL ANTIGEN; CELL SURFACE PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; LY 6 ANTIGEN; LY ANTIGEN; MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; MALE; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SCORING SYSTEM; TUMOR XENOGRAFT;

BIOMEDICAL RESEARCH; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 0036738124     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200209000-00006     Document Type: Review

References (39)

1. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol 1998; 16:2-12.
2. Slovin SF, Kelly WK, Scher HI. Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol 1998; 16:53-59.
3. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first mAb approved for the treatment of lymphoma. Semin Oncol 1999; 26 (5 Suppl. 14):66-73.
4. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p 185HER2/neu mAb plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-2671.
5. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999; 161:960-963.
6. Iughetti P, Suzuki O, Godoi PH, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001; 61:7375-7378.
7. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92:32-41.
8. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001; 28 (5 Suppl. 17):27-33.
9. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998; 95:1735-1740.
10. Classon BJ, Coverdale L. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc Natl Acad Sci U S A 1994; 91:5296-5300.
11. Amoui M, Draber P, Draberova L. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells. Eur J Immunol 1997; 27:1881-1886.
12. Schrijvers AH, Gerretsen M, Fritz JM, et al. Evidence for a role of the mAb E48 defined antigen in cell-cell adhesion in squamous epithelia and head and neck squamous cell carcinoma. Exp Cell Res 1991; 196:264-269.
13. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1286-1296.
14. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62:2546-2553.
15. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001; 61:4660-4665.
16. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61:4320-4324.
17. Dubey P, Wu H, Reiter RE, Witte ON. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 2001; 61:3256-3261.
18. Ross S, Spencer SD, Lasky LA, Koeppen H. Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis. Am J Pathol 2001; 158:809-816.
19. Watabe T, Lin M, Ide H, et al. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A 2002; 99:401-406.
20. Jenks RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524-531.
21. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141-148.
22. Takahashi S, Qian J, Brown JA, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994; 54:3574-3579.
23. Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91:1574-1580.
24. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000; 27:95-103.
25. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000; 89:1329-1348.
26. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7:927-935.
27. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57:3629-3634.
28. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001; 7:2643-2647.
29. Agus DB, Scher HI, Higgins B, et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999; 59:4761-4764.
30. Borgstrom P, Bourdon MA, Hillan KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998; 35:1-10.
31. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60:5522-5528.
32. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001; 98:2658-2663.
33. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97:1392-1398.
34. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25:42-46.
35. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 1998; 17:391-399.
36. Verhagen AP, Aalders TW, Ramaekers FC, et al. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988; 13:25-38.
37. Danielpour D. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci 1999; 112:169-179.
38. Hayward SW, Haughney PC, Lopes ES, et al. The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate 1999; 39:205-212.
39. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987; 11:229-242.